Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.80 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685240 | 0.92 | NR1H2 (0.69) | NR1H2NR1H3MAPTSMN1; SMN2EP300 | |
| SCHEMBL4684768 | 0.91 | NR1H2 (0.69) | NR1H2NR1H3MAPTSMN1; SMN2EP300 | |
| SCHEMBL4688361 | 0.90 | NR1H2 (0.66) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4450601 | 0.89 | NR1H2 (1.00) | NR1H2NR1H3MAPTSMN1; SMN2EP300 | |
| SCHEMBL4684921 | 0.88 | NR1H2 (0.80) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4684805 | 0.85 | NR1H2 (0.64) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4684751 | 0.84 | NR1H2 (0.66) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4685235 | 0.84 | NR1H2 (0.63) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4684032 | 0.83 | NR1H2 (0.59) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4686588 | 0.82 | NR1H2 (0.85) | NR1H2NR1H3MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646625-B1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | claimed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | claimed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | claimed |
| EP-1646625-B1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885MAPT 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.